Key result
This paper describes the protocol for a randomized controlled trial evaluating a 12-week cardiovascular rehabilitation program in 60 patients with rheumatoid arthritis; results are pending.
Why the study?
Does a 12-week cardiovascular rehabilitation programme improve cardiovascular risk factors and systemic inflammation in patients with rheumatoid arthritis?
RCT (n=60)
randomly assigned
Does a 12-week cardiovascular rehabilitation programme improve cardiovascular risk factors and systemic inflammation in patients with rheumatoid arthritis?
This trial protocol outlines a study to determine if a 12-week cardiovascular rehabilitation program is feasible and can reduce cardiovascular risk in patients with rheumatoid arthritis.
INTRODUCTION: Patients with systemic inflammatory diseases such as rheumatoid arthritis (RA) have an increased risk of cardiovascular disease (CVD) above the baseline risk attributable to traditional CVD risk factors seen in the general population. Exercise in cardiac rehabilitation (CR) is designed specifically for high-risk primary prevention and those with established CVD. Even though the European League Against Rheumatism guidelines state that exercise is safe for individuals with RA and exercise can reduce CVD risk, patients with RA rarely participate in CR. Thus, little is known about CR's impact on inflammatory and CVD risk in the RA population. The purpose of this trial is to determine the feasibility of a 12-week CR programme for patients with RA and whether it decreases CVD risk without exacerbating RA. METHODS AND ANALYSIS: This is a randomised controlled trial whereby 60 participants with RA will be recruited and randomly assigned to either standard of care (SOC) treatment or SOC plus a 12-week CR programme (60 min of education plus two 60 min aerobic exercise sessions/week). Exercise will be performed at 60%-80% of heart rate reserve. Outcome measures (Framingham Risk Score, resting heart rate, blood pressure, blood lipids, markers of systemic inflammation (ie, interleukin (IL) 6 and tumour necrosis factor-α (TNF-α), Clinical Disease Assessment Index, Disease Activity Score-28, physical activity levels and peak cardiorespiratory fitness) will be assessed preintervention (week-0), postintervention (week-13) and 6 months postintervention. ETHICS AND DISSEMINATION: Ethical approval was obtained from the Nova Scotia Health Authority Research Ethics Board. Results will be submitted for publication in an appropriate peer-reviewed journal. TRIAL REGISTRATION NUMBER: NCT01534871; Pre-results.
No takes yet. Share an insight, caveat, or question.
Heinze-Milne et al. (2017) conducted an RCT in Rheumatoid arthritis (RA) (n=60). Cardiovascular rehabilitation programme vs. Standard of care (SOC) treatment was evaluated on Feasibility, Framingham Risk Score, resting heart rate, blood pressure, blood lipids, markers of systemic inflammation, and disease activity scores. This paper describes the protocol for a randomized controlled trial evaluating a 12-week cardiovascular rehabilitation program in 60 patients with rheumatoid arthritis; results are pending.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: